HRP20130989T1 - (2r) -2-[(4-sulfonil)aminofenil] propanamidi i farmaceutski sastavi koji ih sadrže - Google Patents
(2r) -2-[(4-sulfonil)aminofenil] propanamidi i farmaceutski sastavi koji ih sadrže Download PDFInfo
- Publication number
- HRP20130989T1 HRP20130989T1 HRP20130989TT HRP20130989T HRP20130989T1 HR P20130989 T1 HRP20130989 T1 HR P20130989T1 HR P20130989T T HRP20130989T T HR P20130989TT HR P20130989 T HRP20130989 T HR P20130989T HR P20130989 T1 HRP20130989 T1 HR P20130989T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino
- phenyl
- propanamide
- sulfonyl
- trifluoromethyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 239000000126 substance Substances 0.000 claims 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 7
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 3
- 229930192474 thiophene Natural products 0.000 claims 3
- VQJWNENDXHSULW-SECBINFHSA-N (2r)-2-[4-(propan-2-ylsulfonylamino)phenyl]propanamide Chemical compound CC(C)S(=O)(=O)NC1=CC=C([C@@H](C)C(N)=O)C=C1 VQJWNENDXHSULW-SECBINFHSA-N 0.000 claims 2
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims 2
- -1 C 1 -C 5 -alkyl Chemical group 0.000 claims 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 159000000000 sodium salts Chemical class 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- WCPCGOOHAZAZNN-BXRBKJIMSA-N (2S)-2-aminopropanamide Chemical compound C[C@H](N)C(N)=O.C[C@H](N)C(N)=O WCPCGOOHAZAZNN-BXRBKJIMSA-N 0.000 claims 1
- YVUJUJYBPUQLQU-ZCFIWIBFSA-N (2r)-2-(4-aminophenyl)propanamide Chemical compound NC(=O)[C@H](C)C1=CC=C(N)C=C1 YVUJUJYBPUQLQU-ZCFIWIBFSA-N 0.000 claims 1
- NOQWLIZWYYEQQZ-LLVKDONJSA-N (2r)-2-[4-(benzenesulfonamido)phenyl]propanamide Chemical compound C1=CC([C@H](C(N)=O)C)=CC=C1NS(=O)(=O)C1=CC=CC=C1 NOQWLIZWYYEQQZ-LLVKDONJSA-N 0.000 claims 1
- BEQYCEOVNHFDKM-SNVBAGLBSA-N (2r)-2-[4-(cyclopentylsulfonylamino)phenyl]propanamide Chemical compound C1=CC([C@H](C(N)=O)C)=CC=C1NS(=O)(=O)C1CCCC1 BEQYCEOVNHFDKM-SNVBAGLBSA-N 0.000 claims 1
- LGGJMOJBOXMPMN-SSDOTTSWSA-N (2r)-2-[4-(methanesulfonamido)phenyl]propanamide Chemical compound NC(=O)[C@H](C)C1=CC=C(NS(C)(=O)=O)C=C1 LGGJMOJBOXMPMN-SSDOTTSWSA-N 0.000 claims 1
- NHHADSKQGRRUPI-SECBINFHSA-N (2r)-2-[4-(thiophen-2-ylsulfonylamino)phenyl]propanamide Chemical compound C1=CC([C@H](C(N)=O)C)=CC=C1NS(=O)(=O)C1=CC=CS1 NHHADSKQGRRUPI-SECBINFHSA-N 0.000 claims 1
- BGQHHMHZWMCYMA-ZCFIWIBFSA-N (2r)-2-[4-(trifluoromethylsulfonylamino)phenyl]propanamide Chemical compound NC(=O)[C@H](C)C1=CC=C(NS(=O)(=O)C(F)(F)F)C=C1 BGQHHMHZWMCYMA-ZCFIWIBFSA-N 0.000 claims 1
- PEURWIYTVKLXFX-SECBINFHSA-N (2r)-2-[4-[(2,6-dichlorophenyl)sulfonylamino]phenyl]propanamide Chemical compound C1=CC([C@H](C(N)=O)C)=CC=C1NS(=O)(=O)C1=C(Cl)C=CC=C1Cl PEURWIYTVKLXFX-SECBINFHSA-N 0.000 claims 1
- BOWWDDNJBCHVSB-CQSZACIVSA-N (2r)-2-[4-[(2-chlorophenyl)sulfonylamino]phenyl]-n-[2-(2-hydroxyethoxy)ethyl]propanamide Chemical compound C1=CC([C@H](C(=O)NCCOCCO)C)=CC=C1NS(=O)(=O)C1=CC=CC=C1Cl BOWWDDNJBCHVSB-CQSZACIVSA-N 0.000 claims 1
- STNRMWZPSZUDLS-LLVKDONJSA-N (2r)-2-[4-[(2-chlorophenyl)sulfonylamino]phenyl]-n-[4-(trifluoromethyl)-1,3-thiazol-2-yl]propanamide Chemical compound O=C([C@H](C)C=1C=CC(NS(=O)(=O)C=2C(=CC=CC=2)Cl)=CC=1)NC1=NC(C(F)(F)F)=CS1 STNRMWZPSZUDLS-LLVKDONJSA-N 0.000 claims 1
- PUVZVGHMIILICS-GFCCVEGCSA-N (2r)-2-[4-[(2-chlorophenyl)sulfonylamino]phenyl]-n-cyclopropylpropanamide Chemical compound O=C([C@H](C)C=1C=CC(NS(=O)(=O)C=2C(=CC=CC=2)Cl)=CC=1)NC1CC1 PUVZVGHMIILICS-GFCCVEGCSA-N 0.000 claims 1
- SYYLTVVRECZCLD-SNVBAGLBSA-N (2r)-2-[4-[(2-chlorophenyl)sulfonylamino]phenyl]propanamide Chemical compound C1=CC([C@H](C(N)=O)C)=CC=C1NS(=O)(=O)C1=CC=CC=C1Cl SYYLTVVRECZCLD-SNVBAGLBSA-N 0.000 claims 1
- BYNPLBVNLHXUER-SNVBAGLBSA-N (2r)-2-[4-[(4-chlorophenyl)sulfonylamino]phenyl]propanamide Chemical compound C1=CC([C@H](C(N)=O)C)=CC=C1NS(=O)(=O)C1=CC=C(Cl)C=C1 BYNPLBVNLHXUER-SNVBAGLBSA-N 0.000 claims 1
- LDPDMLAMANGBQK-LLVKDONJSA-N (2r)-2-[4-[(4-methoxyphenyl)sulfonylamino]phenyl]propanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=C([C@@H](C)C(N)=O)C=C1 LDPDMLAMANGBQK-LLVKDONJSA-N 0.000 claims 1
- YWBJLEJIEQUUHY-GFCCVEGCSA-N (2r)-2-[4-[(4-methylphenyl)sulfonylamino]phenyl]propanamide Chemical compound C1=CC([C@H](C(N)=O)C)=CC=C1NS(=O)(=O)C1=CC=C(C)C=C1 YWBJLEJIEQUUHY-GFCCVEGCSA-N 0.000 claims 1
- DOZZSWAOPDYVLH-SSDOTTSWSA-N (2r)-2-phenylpropanamide Chemical class NC(=O)[C@H](C)C1=CC=CC=C1 DOZZSWAOPDYVLH-SSDOTTSWSA-N 0.000 claims 1
- MGOGKPMIZGEGOZ-REOHCLBHSA-N (2s)-2-amino-3-hydroxypropanamide Chemical compound OC[C@H](N)C(N)=O MGOGKPMIZGEGOZ-REOHCLBHSA-N 0.000 claims 1
- JIUBCAMOSADUGS-GRHHLOCNSA-N (2s)-2-amino-3-phenylpropanamide Chemical compound NC(=O)[C@@H](N)CC1=CC=CC=C1.NC(=O)[C@@H](N)CC1=CC=CC=C1 JIUBCAMOSADUGS-GRHHLOCNSA-N 0.000 claims 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 claims 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 claims 1
- PMLJIHNCYNOQEQ-REOHCLBHSA-N L-aspartic 1-amide Chemical compound NC(=O)[C@@H](N)CC(O)=O PMLJIHNCYNOQEQ-REOHCLBHSA-N 0.000 claims 1
- HKXLAGBDJVHRQG-YFKPBYRVSA-N L-lysinamide Chemical compound NCCCC[C@H](N)C(N)=O HKXLAGBDJVHRQG-YFKPBYRVSA-N 0.000 claims 1
- 206010029888 Obliterative bronchiolitis Diseases 0.000 claims 1
- 229910005948 SO2Cl Inorganic materials 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 201000003848 bronchiolitis obliterans Diseases 0.000 claims 1
- 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 claims 1
- 230000035605 chemotaxis Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 150000003140 primary amides Chemical class 0.000 claims 1
- 150000003222 pyridines Chemical class 0.000 claims 1
- 150000003233 pyrroles Chemical class 0.000 claims 1
- 150000003254 radicals Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 150000003557 thiazoles Chemical class 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/09—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by at least two halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/14—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Claims (10)
1. Derivati (2R)-2-fenilpropanamida formule (I):
[image]
I
i njihove farmaceutski prihvatljive soli,
pri čemu
je R odabran između H, OH, C1-C5-alkila, C3-C6-cikloalkila, C2-C5-alkenila, C1-C5-alkoksila i fenila;
- heteroarilna skupina je odabrana između nesupstituiranog pirola, tiofena, furana, indola, imidazola, tiazola, oksazola, piridina i pirimidina;
- ostatak formule –CH2-CH2-O-(CH2-CH2O)nR'', pri čemu je R'' H ili C1-C5-alkil, n je cijeli broj između 0 i 2;
ili je R, zajedno s NH skupinom za koju je vezan, skupina-radikal primarnih amida prirodnih aminokiselina kao što su (2S)-2-aminopropanamid, (2S)-2-amino-3-fenilpropanamida, (2S)-2-amino-3-hidroksipropanamida, (2S)-2-amino-3-karboksipropanamida, (2S)-2,6-diaminoheksanamida;
je R' odabran između
- linearnog ili razgranatog C1-C5-alkila, C3-C6-cikloalkila, C2-C5-alkenila i trifluormetila;
- nesupstituiranog ili supstituiranog fenila sa skupinom odabranom između halogena, C1-C4-alkila, C1-C4-alkoksila, trifluormetila;
- nesupstituiranog benzila;
- heteroarilne skupine odabrane između nesupstituiranog piridina, pirimidina, pirola, tiofena, furana, indola, tiazola i oksazola;
i sljedećih tvari formule (I):
- (2R)-2-{izopropilsulfonil]amino}fenil)-N-[4-(trifluormetil)-1,3-tiazol-2-il]propanamida i
- (2R)-2-{[(2-klorofenil)sulfonil]amino}fenil)-N-[4-(trifluormetil)-1,3-tiazol-2-il]propanamida.
2. Tvari u skladu s patentnim zahtjevom 1 pri čemu je R odabran između:
H, C1-C5-alkila, C3-C6-cikloalkila, L-2-amino-1-metil-2-oksoetil;
heteroarilne skupine odabrane između nesupstituiranog tiazola, oksazola, piridina;
R' je odabran između:
linearnog ili razgranatog C1-C5-alkila, C3-C6-cikloalkila, trifluormetila i benzila;
nesupstituiranog ili supstituiranog fenila sa skupinom odabranom između halogena, C1-C4-alkila, C1-C4-alkoksila, trifluormetila, tiofena.
3. Tvari u skladu s patentnim zahtjevom 1 ili 2 odabrane između:
(2R)-2-{4-[(izopropilsulfonil]amino}fenil)propanamida;
natrijeve soli (2R)-2-{4-(izopropilsulfonil]amino}fenil)propanamida;
(2R)-2-{4-{[(2-klorfenil)sulfonil]amino}fenil)propanamida;
(2R)-2-{4-{[(2,6-diklorfenil)sulfonil]amino}fenil)propanamida;
(2R)-2-{4-[(metilsulfonil)amino]fenil}propanamida;
(2R)-2-{4-[(fenilsulfonil)amino]fenil}propanamida;
(2R)-2-{4-{[(4-metilfenil)sulfonil]amino}fenil)propanamida;
(2R)-2-{4-{[(4-metoksifenil)sulfonil]amino}fenil)propanamida;
(2R)-2-(4-[(benzilsulfonil)amino}fenil)propanamida;
(2R)-2-(4-{[(4-klorfenil)sulfonil]amino}fenil)propanamida;
(2R)-2-(4-{[(4-trifluormetil)fenil]sulfonil}amino)fenil]propanamida;
(2R)-2-{4-[(tien-2ilsulfonil)amino]fenil}propanamida;
(2R)-2-{4-[(ciklopentilsulfonil)amino]fenil}propanamida;
(2R)-2-(4-{[(trifluormetil) sulfonil]amino}fenil)propanamida;
(2R)-2-{4-[(izopropilsulfonil]amino}fenil)-N-metilpropanamida;
(2R)-N-[(1S)-2-amino-1-metil-2-oksoetil]-2-{4-[(izopropilsulfonil]amino}fenil)propanamida;
(2R)-2-{4-[(izopropilsulfonil]amino}fenil)-N-[4-(trifluormetil)-1,3-tiazol-2-il]propanamida;
(2R)-2-{4-{[(2-klorfenil)sulfonil]amino}fenil)-N-[4-(trifluormetil)-1,3-tiazol-2-il]propanamida;
(2R)-2-{4-{[(2-klorfenil)sulfonil]amino}fenil)-N-[2-(2-hidroksietoksi)etil]propanamida;
(2R)-2-{4-{[(2-klorfenil)sulfonil]amino}fenil)-N-ciklopropilpropanamida
4. Tvari u skladu s bilo kojim od patentnih zahtjeva 1 do 3 koje su: (2R)-2-{4-[(izopropilsulfonil]amino}fenil)propanamid i njegove natrijeve soli.
5. Tvari u skladu s bilo kojim od patentnih zahtjeva 1 do 4 za uporabu kao medikamenti.
6. Uporaba tvari u skladu s bilo kojim od patentnih zahtjeva 1 do 4 u pripremi medikamenta za liječenje bolesti koje uključuju CXCL1 induciranu kemotaksiju ljudskih PMNa.
7. Uporaba tvari u skladu s bilo kojim od patentnih zahtjeva 1 do 4 u pripremi medikamenta za liječenje melanoma, angiogeneze, kronične opstruktivne bolesti pluća (COPD) i sindroma bronhiolitisa obliteransa (BOS).
8. Farmaceutski sastavi koji obuhvaćaju tvar u skladu s bilo kojim od patentnih zahtjeva 1 do 4 uz primjesu za njih odgovarajućeg nosača.
9. Postupak za pripravu tvari formule (I) u skladu s patentnim zahtjevom 1 obuhvaća reakciju tvari formule (II),
[image]
(II)
pri čemu R' ima isto značenje kako je definirano u patentnom zahtjevu 1, s jednim aminom formule NHR, pri čemu R ima isto značenje kako je definirano u patentnom zahtjevu 1.
10. Postupak za pripravu tvari formule (I) u skladu s patentnim zahtjevom 1 obuhvaća reakciju (2R)-2-(4-aminofenil)propanamida sa sulfonil kloridom formule R'SO2Cl, pri čemu R' ima isto značenje kako je definirano u patentnom zahtjevu 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06114185 | 2006-05-18 | ||
| PCT/EP2007/054806 WO2007135080A2 (en) | 2006-05-18 | 2007-05-17 | (2r)-2-[(4-sulfonyl)aminophenyl]propanamides and pharmaceutical compositions containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130989T1 true HRP20130989T1 (hr) | 2013-12-06 |
Family
ID=38353147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130989TT HRP20130989T1 (hr) | 2006-05-18 | 2013-10-21 | (2r) -2-[(4-sulfonil)aminofenil] propanamidi i farmaceutski sastavi koji ih sadrže |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7652169B2 (hr) |
| EP (1) | EP2024329B1 (hr) |
| JP (1) | JP5161873B2 (hr) |
| KR (1) | KR101422299B1 (hr) |
| CN (1) | CN101448784B (hr) |
| AU (1) | AU2007253424B2 (hr) |
| BR (1) | BRPI0712064B8 (hr) |
| CA (1) | CA2649794C (hr) |
| CY (1) | CY1114532T1 (hr) |
| DK (1) | DK2024329T3 (hr) |
| ES (1) | ES2433095T3 (hr) |
| HK (1) | HK1131380A1 (hr) |
| HR (1) | HRP20130989T1 (hr) |
| IL (1) | IL194939A (hr) |
| MX (1) | MX2008013957A (hr) |
| NZ (1) | NZ572075A (hr) |
| PL (1) | PL2024329T3 (hr) |
| PT (1) | PT2024329E (hr) |
| RS (1) | RS53007B (hr) |
| RU (1) | RU2457201C2 (hr) |
| SI (1) | SI2024329T1 (hr) |
| WO (1) | WO2007135080A2 (hr) |
| ZA (1) | ZA200808907B (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2166006A1 (en) * | 2008-09-18 | 2010-03-24 | Dompe' S.P.A. | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them |
| KR101298651B1 (ko) | 2011-03-16 | 2013-08-21 | 연세대학교 산학협력단 | 효능이 강화된 혈관신생 억제용 약제학적 조성물 |
| CN103159674A (zh) * | 2013-04-03 | 2013-06-19 | 苏州安诺生物医药技术有限公司 | 2-苯烷酰胺类化合物及其制备方法、药物组合物和用途 |
| CN110420316A (zh) | 2013-06-18 | 2019-11-08 | 纽约大学 | 参与金黄色葡萄球菌杀白细胞素的细胞毒性的细胞因素：新型治疗靶点 |
| BR112017002060A2 (pt) * | 2014-07-31 | 2017-12-26 | Glaxosmithkline Ip Dev Ltd | novo uso |
| EP3884932A1 (en) | 2020-03-26 | 2021-09-29 | Dompe' Farmaceutici S.P.A. | Cxcl8 inhibitors for use in the treatment of covid-19 |
| EP4008325A1 (en) | 2020-12-02 | 2022-06-08 | Dompe' Farmaceutici S.P.A. | Cxcl8 inhibitors for use in the treatment of covid-19 |
| EP4125848A1 (en) | 2020-03-26 | 2023-02-08 | Dompe' Farmaceutici SpA | Cxcl8 inhibitors for use in the treatment of covid-19 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN188162B (hr) * | 1999-02-05 | 2002-08-31 | Torrent Pharmaceuticals Ltd | |
| IT1317826B1 (it) * | 2000-02-11 | 2003-07-15 | Dompe Spa | Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8. |
| ITMI20012434A1 (it) * | 2001-11-20 | 2003-05-20 | Dompe Spa | Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono |
| EP1457485A1 (en) * | 2003-03-14 | 2004-09-15 | Dompé S.P.A. | Sulfonic acids, their derivatives and pharmaceutical compositions containing them |
| KR100707123B1 (ko) * | 2003-07-02 | 2007-04-16 | 그뤼넨탈 게엠베하 | 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 4-(메틸설포닐아미노)페닐 동족체 및 이를함유하는 약학적 조성물 |
| CA2553705C (en) * | 2004-03-23 | 2012-12-11 | Dompe S.P.A. | 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them |
| NZ555502A (en) * | 2004-12-15 | 2010-12-24 | Dompe Pha R Ma Spa Res & Mfg | 2-arylpropionic acid derivatives and pharmaceutical compositions containing them |
-
2007
- 2007-05-17 SI SI200731344T patent/SI2024329T1/sl unknown
- 2007-05-17 NZ NZ572075A patent/NZ572075A/en unknown
- 2007-05-17 PT PT77292548T patent/PT2024329E/pt unknown
- 2007-05-17 DK DK07729254.8T patent/DK2024329T3/da active
- 2007-05-17 RU RU2008149936/04A patent/RU2457201C2/ru active
- 2007-05-17 KR KR1020087027557A patent/KR101422299B1/ko active IP Right Grant
- 2007-05-17 ZA ZA200808907A patent/ZA200808907B/xx unknown
- 2007-05-17 PL PL07729254T patent/PL2024329T3/pl unknown
- 2007-05-17 ES ES07729254T patent/ES2433095T3/es active Active
- 2007-05-17 MX MX2008013957A patent/MX2008013957A/es active IP Right Grant
- 2007-05-17 EP EP07729254.8A patent/EP2024329B1/en active Active
- 2007-05-17 CA CA2649794A patent/CA2649794C/en active Active
- 2007-05-17 JP JP2009510463A patent/JP5161873B2/ja active Active
- 2007-05-17 WO PCT/EP2007/054806 patent/WO2007135080A2/en active Application Filing
- 2007-05-17 RS RS20130467A patent/RS53007B/en unknown
- 2007-05-17 CN CN2007800179024A patent/CN101448784B/zh active Active
- 2007-05-17 US US12/227,519 patent/US7652169B2/en active Active
- 2007-05-17 BR BRPI0712064A patent/BRPI0712064B8/pt active IP Right Grant
- 2007-05-17 AU AU2007253424A patent/AU2007253424B2/en active Active
-
2008
- 2008-10-27 IL IL194939A patent/IL194939A/en active IP Right Grant
-
2009
- 2009-10-30 HK HK09110159.7A patent/HK1131380A1/xx unknown
- 2009-12-15 US US12/653,599 patent/US7868046B2/en active Active
-
2013
- 2013-10-21 HR HRP20130989TT patent/HRP20130989T1/hr unknown
- 2013-10-25 CY CY20131100949T patent/CY1114532T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130989T1 (hr) | (2r) -2-[(4-sulfonil)aminofenil] propanamidi i farmaceutski sastavi koji ih sadrže | |
| RU2397168C2 (ru) | Производные тиофена в качестве ингибиторов снк 1 | |
| CA2909742C (en) | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| JP6440321B2 (ja) | スルホンアミド誘導体またはその薬学的に許容される酸付加塩 | |
| CA2899706C (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b | |
| ES2353077T3 (es) | Derivados de urea con sustitución en posición 3 y uso medicinal de los mismos. | |
| RU2009118254A (ru) | Фенилацетамиды в качестве ингибиторов протеинкиназ | |
| RU2014119976A (ru) | (гетеро)арилциклопропиламины в качестве ингибиторов lsd1 | |
| JP4751567B2 (ja) | 新規アミド誘導体およびその医薬としての用途 | |
| LT3302B (en) | Novel sulfonamide inhibitors of aspartyl protease | |
| JP2013010793A5 (hr) | ||
| RU2005101406A (ru) | Производные пиримидинсульфонамида в качестве модуляторов рецепторов хемокинов | |
| HRP20090681T1 (hr) | Derivati 2-fenilpropionske kiseline i farmaceutski pripravci koji ih sadrže | |
| RU2014132884A (ru) | Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунных и аутоиммунных заболеваний | |
| RU2007106037A (ru) | Производные пиримидисульфонамида в качестве модуляторов рецепторов хемокинов | |
| HRP20161260T1 (hr) | Derivati (r)-arilkilamina i farmaceutski pripravci koji ih sadrže | |
| EA200601287A1 (ru) | Производные (3-оксо-3,4-дигидрохиноксалин-2-иламино) бензамида и родственные соединения в качестве ингибиторов гликогенфосфорилазы для лечения диабета и ожирения | |
| CA3008611A1 (en) | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
| JP2005505586A5 (hr) | ||
| RU2016134130A (ru) | ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ В КАЧЕСТВЕ ПРОТИВОВИРУСНЫХ СОЕДИНЕНИЙ | |
| HRP20110436T1 (hr) | Supstituirani karboksamidi kao antagonisti metabotropnih receptora iz skupine i | |
| RU2007122450A (ru) | Применение агониста рецептора 5-нт6 для лечения и профилактики нейродегенеративных заболеваний | |
| JP2007516211A5 (hr) | ||
| RU2013147449A (ru) | Фармацевтическая композиция для профилактики или лечения макулярной дегенерации | |
| AU2012268119B2 (en) | [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid |